Skip to main content

Advertisement

SpringerLink
Log in

Mechanisms of platelet recovery in ITP associated with therapy

  • Basic Science
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease primarily characterized by increased clearance of auto-antibody-sensitized platelets by Fc-receptor-bearing macrophages in the spleen and liver. It has been classically accepted that antibody-mediated platelet destruction is Fc dependent. Recent studies, however, may also indicate the involvement of Fc-independent pathways of platelet destruction. Current treatment options work by immunosuppression (e.g., corticosteroids), immunomodulation (e.g., IVIg and anti-D), or removal of the platelet destruction site (splenectomy) in ITP. This review will discuss the mechanisms of action of these and other treatments for ITP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Crow AR, Lazarus AH (2003) Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 25(Suppl 1):S14–S18

    Article  PubMed  Google Scholar 

  2. Jin F, Balthasar JP (2005) Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol 66(4):403–410

    Article  CAS  PubMed  Google Scholar 

  3. Kuter DJ, Gernsheimer TB (2009) Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am 23(6):1193–1211

    Article  PubMed  Google Scholar 

  4. Rodeghiero F et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393

    Article  CAS  PubMed  Google Scholar 

  5. Provan D et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186. doi:10.1182/blood-06-225565

    Article  CAS  PubMed  Google Scholar 

  6. Olsson B et al (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9(9):1123–1124

    Article  CAS  PubMed  Google Scholar 

  7. Zhang F et al (2006) Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76(5):427–431

    Article  CAS  PubMed  Google Scholar 

  8. Zhang W et al (2009) Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 113(17):4086–4093

    Article  CAS  PubMed  Google Scholar 

  9. Webster ML et al (2006) Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 108(3):943–946

    Article  CAS  PubMed  Google Scholar 

  10. Wright JF et al (1996) Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol 95(1):145–152

    Article  CAS  PubMed  Google Scholar 

  11. Kuwana M et al (2002) Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 168(7):3675–3682

    CAS  PubMed  Google Scholar 

  12. Crow AR, Lazarus AH (2008) The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 22(2):103–116

    Article  PubMed  Google Scholar 

  13. Aslam R et al (2007) Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells. Transfusion 47(11):2161–2168

    Article  CAS  PubMed  Google Scholar 

  14. Chan H et al (2003) The IgG subclasses of platelet-associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol 122(5):818–824

    Article  CAS  PubMed  Google Scholar 

  15. Go RS, Johnston KL, Bruden KC (2007) The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 92(2):283–284

    Article  PubMed  Google Scholar 

  16. Nieswandt B et al (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96(7):2520–2527

    CAS  PubMed  Google Scholar 

  17. Nardi M et al (2004) Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway. J Clin Invest 113(7):973–980

    CAS  PubMed  Google Scholar 

  18. Hed J (1998) Role of complement in immune or idiopathic thrombocytopenic purpura. Acta Paediatr Suppl 424:37–40

    Article  CAS  PubMed  Google Scholar 

  19. Cole TJ (2006) Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnology Ann Rev 12:269–300

    Article  CAS  Google Scholar 

  20. Fehr J, Hofmann V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306(21):1254–1258

    Article  CAS  PubMed  Google Scholar 

  21. Berchtold P et al (1989) Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 74(7):2414–2417

    CAS  PubMed  Google Scholar 

  22. Hansen RJ, Balthasar JP (2002) Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost 88(6):898–899

    CAS  PubMed  Google Scholar 

  23. Bayry J et al (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101(2):758–765

    Article  CAS  PubMed  Google Scholar 

  24. Siragam V et al (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12(6):688–692

    Article  CAS  PubMed  Google Scholar 

  25. Anthony RM et al (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 105(50):19571–19578

    Article  CAS  PubMed  Google Scholar 

  26. Samuelsson A et al (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291(5503):484–486

    Article  CAS  PubMed  Google Scholar 

  27. Stasi R, Provan D (2004) Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79(4):504–522

    Article  PubMed  Google Scholar 

  28. Newman GC et al (2001) A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 112(4):1076–1078

    Article  CAS  PubMed  Google Scholar 

  29. Salama A et al (1984) Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D)]. Blut 49(1):29–35

    Article  CAS  PubMed  Google Scholar 

  30. Ambriz-Fernandez R et al (2002) Fc receptor blockade in patients with refractory chronic immune thrombocytopenic purpura with anti-D IgG. Arch Med Res 33(6):536–540

    Article  CAS  PubMed  Google Scholar 

  31. Boughton BJ et al (1994) Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment. Autoimmunity 18(2):141–144

    Article  CAS  PubMed  Google Scholar 

  32. Song S et al (2005) Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105(4):1546–1548

    Article  CAS  PubMed  Google Scholar 

  33. Stasi R et al (2009) Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 113(6):1231–1240

    Article  CAS  PubMed  Google Scholar 

  34. Franchini M et al (2007) Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 60(2):237–246

    Article  CAS  PubMed  Google Scholar 

  35. Asahi A et al (2008) Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest 118(8):2939–2949

    CAS  PubMed  Google Scholar 

  36. Stasi R et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110(8):2924–2930

    Article  CAS  PubMed  Google Scholar 

  37. Stasi R et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112(4):1147–1150

    Article  CAS  PubMed  Google Scholar 

  38. Erickson-Miller CL et al (2005) Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 33(1):85–93

    Article  CAS  PubMed  Google Scholar 

  39. Cohn CS, Bussel JB (2009) Romiplostim: a second-generation thrombopoietin agonist. Drugs Today (Barc) 45(3):175–188

    Article  Google Scholar 

  40. Bussel JB et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22):2237–2247

    Article  CAS  PubMed  Google Scholar 

  41. Kuter DJ et al (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610):395–403

    Article  CAS  PubMed  Google Scholar 

  42. Gernsheimer TB (2008) The pathophysiology of itp revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2008:219–226

    Google Scholar 

  43. Podolanczuk A et al (2009) Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113(14):3154–3160

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Canadian Blood Services, Toronto, ON, Canada

    Sophie J. Y. Pang & Alan H. Lazarus

  2. The Keenan Research Centre, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, ON, Canada

    Sophie J. Y. Pang & Alan H. Lazarus

  3. The Toronto Platelet Immunobiology Group and The Departments of Medicine, Laboratory Medicine & Pathobiology of the University of Toronto, Toronto, ON, Canada

    Sophie J. Y. Pang & Alan H. Lazarus

  4. St. Michael’s Hospital, 30 Bond Street, Toronto, ON, Canada, M5B 1W8

    Alan H. Lazarus

Authors
  1. Sophie J. Y. Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alan H. Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alan H. Lazarus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pang, S.J.Y., Lazarus, A.H. Mechanisms of platelet recovery in ITP associated with therapy. Ann Hematol 89 (Suppl 1), 31–35 (2010). https://doi.org/10.1007/s00277-010-0916-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-010-0916-2

Keywords

Search

Navigation